secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2024-11-26T23:59:59+00:00
Accession:  0001213900-24-102899
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma changes fiscal year end to Dec 31, transition period Jul-Dec 2024
--------------------------------------------------------------------------------

- Board approved fiscal year change from June 30 to December 31 effective November 25, 2024.
- Transition period covers July 1, 2024 through December 31, 2024.
- Company will file Form 10-KT with audited financials for the transition period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024102899/0001213900-24-102899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024102899/ea0222615-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-102899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer